ADAPTIVE BIOTECHNOLOGIES CORPORATION APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.12M, a 16.77% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $11.93M, a 1.80% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $12.72M, a 0.87% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $13.26M, a 1.96% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $51.48M, a 3.97% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $53.61M, a 14.78% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $62.91M, a 13.39% increase from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $55.48M, a 28.27% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.12M 10-Q · filed 2026-08-04 | $23.05M 10-Q · filed 2026-08-04 | $35.77M derived: sum of 3 quarters · filed 2026-08-04 | $49.02M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $11.93M 10-Q · filed 2026-05-05 | $24.65M derived: sum of 2 quarters · filed 2026-05-05 | $37.91M derived: sum of 3 quarters · filed 2026-05-05 | $51.26M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $12.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.98M derived: sum of 2 quarters · filed 2026-02-26 | $39.34M derived: sum of 3 quarters · filed 2026-08-04 | $51.48M 10-K · filed 2026-02-26 |
| 2025-09-30 | $13.26M 10-Q · filed 2025-11-05 | $26.62M derived: sum of 2 quarters · filed 2026-08-04 | $38.76M 10-Q · filed 2025-11-05 | $51.59M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $13.36M 10-Q · filed 2026-08-04 | $25.51M 10-Q · filed 2026-08-04 | $38.34M derived: sum of 3 quarters · filed 2026-08-04 | $51.86M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $12.15M 10-Q · filed 2026-05-05 | $24.98M derived: sum of 2 quarters · filed 2026-05-05 | $38.50M derived: sum of 3 quarters · filed 2026-05-05 | $51.46M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $12.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.35M derived: sum of 2 quarters · filed 2026-02-26 | $39.31M derived: sum of 3 quarters · filed 2026-02-26 | $53.61M 10-K · filed 2026-02-26 |
| 2024-09-30 | $13.52M 10-Q · filed 2025-11-05 | $26.48M derived: sum of 2 quarters · filed 2025-11-05 | $40.78M 10-Q · filed 2025-11-05 | $56.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $12.96M 10-Q · filed 2025-08-05 | $27.26M 10-Q · filed 2025-08-05 | $42.81M derived: sum of 3 quarters · filed 2026-02-26 | $58.15M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $14.30M 10-Q · filed 2025-05-01 | $29.85M derived: sum of 2 quarters · filed 2026-02-26 | $45.19M derived: sum of 3 quarters · filed 2026-02-26 | $62.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $15.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $30.89M derived: sum of 2 quarters · filed 2026-02-26 | $48.24M derived: sum of 3 quarters · filed 2026-02-26 | $62.91M 10-K · filed 2026-02-26 |
| 2023-09-30 | $15.34M 10-Q · filed 2024-11-07 | $32.68M derived: sum of 2 quarters · filed 2024-11-07 | $47.35M 10-Q · filed 2024-11-07 | $61.65M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $17.34M 10-Q · filed 2024-08-01 | $32.02M 10-Q · filed 2024-08-01 | $46.31M derived: sum of 3 quarters · filed 2025-03-03 | $60.45M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $14.67M 10-Q · filed 2024-05-07 | $28.96M derived: sum of 2 quarters · filed 2025-03-03 | $43.11M derived: sum of 3 quarters · filed 2025-03-03 | $57.29M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $14.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $28.44M derived: sum of 2 quarters · filed 2025-03-03 | $42.62M derived: sum of 3 quarters · filed 2025-03-03 | $55.48M 10-K · filed 2025-03-03 |
| 2022-09-30 | $14.14M 10-Q · filed 2023-11-09 | $28.32M derived: sum of 2 quarters · filed 2023-11-09 | $41.18M 10-Q · filed 2023-11-09 | $53.06M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $14.18M 10-Q · filed 2023-08-02 | $27.04M 10-Q · filed 2023-08-02 | $38.92M derived: sum of 3 quarters · filed 2024-02-29 | $50.56M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $12.86M 10-Q · filed 2023-05-03 | $24.74M derived: sum of 2 quarters · filed 2024-02-29 | $36.38M derived: sum of 3 quarters · filed 2024-02-29 | $47.63M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $11.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $23.52M derived: sum of 2 quarters · filed 2024-02-29 | $34.77M derived: sum of 3 quarters · filed 2024-02-29 | $43.25M 10-K · filed 2024-02-29 |
| 2021-09-30 | $11.64M 10-Q · filed 2022-11-03 | $22.89M derived: sum of 2 quarters · filed 2022-11-03 | $31.38M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $11.25M 10-Q · filed 2022-08-03 | $19.73M 10-Q · filed 2022-08-03 | ||
| 2020-12-31 | $24.76M 10-K · filed 2023-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |